GNTA Stock Overview
A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genenta Science S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.83 |
| 52 Week High | US$7.28 |
| 52 Week Low | US$2.20 |
| Beta | 0.74 |
| 1 Month Change | -24.75% |
| 3 Month Change | -21.84% |
| 1 Year Change | 21.97% |
| 3 Year Change | -56.04% |
| 5 Year Change | n/a |
| Change since IPO | -65.18% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Genenta Science's (NASDAQ:GNTA) Cash Burn Rate
Jan 26
We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely
Jul 21We're Not Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn
Dec 10We're Hopeful That Genenta Science (NASDAQ:GNTA) Will Use Its Cash Wisely
Sep 09Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach
Jul 25Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?
Mar 18Shareholder Returns
| GNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.8% | -1.1% | -0.3% |
| 1Y | 22.0% | -2.3% | 20.4% |
Return vs Industry: GNTA exceeded the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: GNTA matched the US Market which returned 22% over the past year.
Price Volatility
| GNTA volatility | |
|---|---|
| GNTA Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GNTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GNTA's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 14 | Pierluigi Paracchi | www.genenta.com |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
Genenta Science S.p.A. Fundamentals Summary
| GNTA fundamental statistics | |
|---|---|
| Market cap | US$72.06m |
| Earnings (TTM) | -US$9.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.6x
P/E RatioIs GNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNTA income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €8.92m |
| Earnings | -€8.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GNTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 05:27 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genenta Science S.p.A. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Emanuela Branchetti | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |